ReviewFrontiers in immunology2020
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).
Open access · goldAbstract readReview
In one paragraph
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 4 pooled it
12.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 4 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- A new hope with CAR T-cell therapy for refractory idiopathic inflammatory myopathies: a systematic review.Journal of translational medicine · 2026Pooled it
- Hemophagocytic Lymphohistiocytosis in the adult critically ill: a narrative review of case reports and case series.Frontiers in medicine · 2025Pooled it
- A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator.Iranian biomedical journal · 2024Pooled it
- 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Cancer biology & medicine · 2023Guideline
- Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.Blood advances · 2022Trial
- Gastrointestinal Toxoplasmosis in a Heart Transplant Recipient.Open forum infectious diseases · 2026Article
- Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome during treatment with the bivalent CD20xCD3 bispecific antibody glofitamab.Haematologica · 2026Article
- Review
- Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management.Chinese medical journal · 2026Review
- Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study.Blood advances · 2026Article
- Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact.Bone marrow transplantation · 2026Article
- Hemophagocytic Syndromes in Adults: Real-World Data on Mortality from a Tertiary Reference Center.Acta haematologica · 2026Article
- Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up.Drug safety · 2026Review
- Intensive Care management of Hemophagocytic Lymphohistiocytosis: a case series.BMC anesthesiology · 2025Article
- Clinical manifestations and outcomes of EBV-related secondary hemophagocytic lymphohistiocytosis.Annals of hematology · 2025Article
- Article
- Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).Molecular medicine reports · 2025Review
- Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.Haematologica · 2025Review
- Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.Bone marrow transplantation · 2025Review
- The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy.Current treatment options in oncology · 2025Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 13 institutions in 9 countries.
Robert David SandlerDepartment of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Rachel Scarlett TattersallDepartment of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Helene SchoemansDepartment of Hematology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Raffaella GrecoHaematology and BMT Unit, San Raffaele Hospital (IRCCS), Milan, Italy.
Manuela BadoglioEBMT Paris Study Office, Department of Haematology, Hôpital Saint-Antoine, Paris, France.
Myriam LabopinEBMT Paris Study Office, Department of Haematology, Hôpital Saint-Antoine, Paris, France.
Tobias AlexanderDepartment of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Kirill KirgizovRussian Cancer Research Center NN Blokhin, Moscow, Russia.
Montserrat RoviraBMT Unit, Department of Hematology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Muhammad SaifManchester Royal Infirmary, Manchester, United Kingdom.
Riccardo SaccardiCell Therapy and Transfusion Medicine Unit, Careggi Hospital, Florence, Italy.
Julio DelgadoBMT Unit, Department of Hematology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Zinaida PericSchool of Medicine, University of Zagreb, Zagreb, Croatia.
Christian KoeneckeDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany.
Olaf PenackDepartment of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Grzegorz BasakDepartment of Hematology, Oncology and Internal Medicine, University Clinical Center of the Medical University of Warsaw, Warsaw, Poland.
John Andrew SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Sheffield Teaching Hospitals NHS Foundation Trust · GBCharité - Universitätsmedizin Berlin · DEConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESAzienda Ospedaliero-Universitaria Careggi · ITHôpital Saint-Antoine · FRIstituti di Ricovero e Cura a Carattere Scientifico · ITKU Leuven · BEManchester Royal Infirmary · GBMedical University of Warsaw · PLMedizinische Hochschule Hannover · DERussian Cancer Research Center NN Blokhin · RUSorbonne Université · FRUniversity Hospital Centre Zagreb · HR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultFemaleHematopoietic Stem Cell TransplantationHumansImmunotherapy, AdoptiveLymphohistiocytosis, HemophagocyticMacrophage Activation SyndromeMaleMiddle AgedReceptors, Chimeric AntigenSurveys and QuestionnairesReceptors, Chimeric AntigenbiomarkersCAR-T cellferritinGVHDHLH hemophagocytic lymphohistiocytosisHSCTmacrophage activation syndrome (MAS)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.